表紙
市場調查報告書

雌激素受體β:開發中產品分析

Estrogen Receptor Beta - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 557378
出版日期 內容資訊 英文 80 Pages
訂單完成後即時交付
價格
雌激素受體β:開發中產品分析 Estrogen Receptor Beta - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 80 Pages
簡介

本報告提供以雌激素受體β為標的之治療藥開發平台現狀及最新更新之各開發階段比較分析,提供涵括了最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

雌激素受體β;概要

雌激素受體β;治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Acadia Pharmaceuticals Inc
  • AstraZeneca Plc
  • Atossa Genetics Inc
  • Chamaeleo Pharma NV
  • Eli Lilly and Company
  • Endece LLC
  • EndoCeutics Inc
  • Karo Pharma AB
  • Kissei藥品工業
  • MEI Pharma Inc
  • Mithra Pharmaceuticals SA
  • Oasmia Pharmaceutical AB

藥物簡介

暫停中的產品

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2037TDB

Summary

According to the recently published report 'Estrogen Receptor Beta - Pipeline Review, H2 2019'; Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) pipeline Target constitutes close to 21 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes.

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Estrogen receptor beta (ERB) is a nuclear receptor that is activated by the sex hormone estrogen. It is encoded by the gene ESR2. Upon binding to 17beta-estradiol or related ligands, the encoded protein forms homo- or hetero-dimers that interact with specific DNA sequences to activate transcription.

The report 'Estrogen Receptor Beta - Pipeline Review, H2 2019' outlays comprehensive information on the Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 5, 3 and 6 respectively. Similarly, the universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 2 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Musculoskeletal Disorders, Women's Health, Immunology, Male Health and Metabolic Disorders which include indications Multiple Sclerosis, Osteoporosis, Breast Cancer, Prostate Cancer, Triple-Negative Breast Cancer (TNBC), Alzheimer's Disease, Bile Duct Cancer (Cholangiocarcinoma), Carcinomas, Chemotherapy Induced Pain, Cognitive Impairment Associated With Schizophrenia (CIAS), Colon Cancer, Demyelinating Diseases, Depression, Ductal Carcinoma In Situ, Endometrial Cancer, Endometriosis, Fallopian Tube Cancer, Hormone Sensitive Breast Cancer, Inflammation, Male Hypogonadism, Malignant Pleural Mesothelioma, Neuromyelitis Optica (Devic's Syndrome), Obesity, Ovarian Cancer, Peritoneal Cancer, Post Menopausal Mood Disorder, Uterine Cancer and Vasomotor Symptoms of Menopause (Hot Flashes).

Scope

  • The report provides a snapshot of the global therapeutic landscape for Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2)
  • The report reviews Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Overview
  • Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Companies Involved in Therapeutics Development
  • Acadia Pharmaceuticals Inc
  • AstraZeneca Plc
  • Atossa Genetics Inc
  • Avivia BV
  • Eagle Pharmaceuticals Inc
  • Eli Lilly and Co
  • Endece LLC
  • EndoCeutics Inc
  • Helixmith Co Ltd
  • Huons Co Ltd
  • Karo Pharma AB
  • Kissei Pharmaceutical Co Ltd
  • MEI Pharma Inc
  • Oasmia Pharmaceutical AB
  • Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Drug Profiles
  • (bazedoxifene acetate + cholecalciferol) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AC-186 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • acolbifene + prasterone - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AUS-131 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • dehydrodiconiferyl alcohol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drug to Agonize ER-Beta for Multiple Sclerosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • erteberel - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • estradiol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • fosfestrol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • fulvestrant - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • fulvestrant - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • fulvestrant - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KB-3944 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KB-9520 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Libidua - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Loseasonique - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NDC-1308 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Agonize ESR2 for Obesity and Depression - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Agonize ESR2 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Agonize ESR2 for Multiple Sclerosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Agonize Estrogen Beta Receptor for Inflammatory Diseases and Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SR-16234 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Dormant Products
  • Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Discontinued Products
  • Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Product Development Milestones
  • Featured News & Press Releases
  • Dec 09, 2019: Eagle Pharmaceuticals commences dosing in pilot study for novel estrogen receptor antagonist product candidate
  • Oct 16, 2019: Atossa Genetics receives IRB approval for phase 2 breast cancer study using intraductal technology
  • Aug 05, 2019: Eagle Pharmaceuticals announces Clinical Development Plan of innovative product intended to deliver maximum Estrogen Receptor inhibition in patients with Estrogen Receptor (ER)-Positive Breast Cancer
  • Mar 27, 2019: Combo better for HR+ breast cancer patients
  • Oct 30, 2018: Eagle Pharmaceuticals announces results of study for fulvestrant
  • Oct 20, 2018: New option for women with advanced breast cancer resistant to hormone therapy
  • Oct 04, 2018: Mayo researchers identify potential new treatment for subset of women with triple-negative breast cancer
  • Jun 01, 2018: ENDECE Attending 2018 Bio International in Boston
  • Mar 26, 2018: Mayne Pharma Launches Generic Quartette in the U.S., Another Womens Health Product
  • Dec 11, 2017: AstraZeneca's Faslodex Rejects For Use Within NHS Scotland
  • Dec 07, 2017: Eagle Pharmaceuticals Commences Pivotal Study for Fulvestrant
  • Nov 15, 2017: Faslodex receives US FDA approval for the treatment of advanced breast cancer in combination with abemaciclib
  • Nov 14, 2017: Faslodex (Fulvestrant) Receives EU Approval for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer in Combination with Palbociclib
  • Oct 13, 2017: Faslodex (Fulvestrant) Receives Positive CHMP Opinion For The Treatment Of Hormone Receptor-Positive Advanced Breast Cancer In Combination With Palbociclib
  • Sep 01, 2017: NICE says benefits of breast cancer drug fulvestrant too uncertain to make it cost effective
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Acadia Pharmaceuticals Inc, H2 2019
  • Pipeline by AstraZeneca Plc, H2 2019
  • Pipeline by Atossa Genetics Inc, H2 2019
  • Pipeline by Avivia BV, H2 2019
  • Pipeline by Eagle Pharmaceuticals Inc, H2 2019
  • Pipeline by Eli Lilly and Co, H2 2019
  • Pipeline by Endece LLC, H2 2019
  • Pipeline by EndoCeutics Inc, H2 2019
  • Pipeline by Helixmith Co Ltd, H2 2019
  • Pipeline by Huons Co Ltd, H2 2019
  • Pipeline by Karo Pharma AB, H2 2019
  • Pipeline by Kissei Pharmaceutical Co Ltd, H2 2019
  • Pipeline by MEI Pharma Inc, H2 2019
  • Pipeline by Oasmia Pharmaceutical AB, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Dormant Products, H2 2019 (Contd..2), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019